Latest Safety News

Bio-Gene Technology Limited has secured A$3 million in U.S. Department of Defense grants to accelerate development of its two nature-derived insecticides, Flavocide and Qcide, targeting both military and civilian markets.

Vonex Limited has announced a $13.9 million non-renounceable entitlement offer to reduce its substantial debt, with major shareholder Maxo Telecommunications underwriting the raise. The move comes as CEO Ian Porter prepares to depart, marking a pivotal moment for the telecommunications provider.

Emyria reports sustained and statistically significant improvements in PTSD symptoms and quality of life three months after MDMA-assisted therapy, signaling a potential breakthrough for treatment-resistant patients.

Argenica Therapeutics has reported compelling preclinical data showing ARG-007 significantly reduces brain cell damage and inflammation in moderate traumatic brain injury, matching levels seen in uninjured controls. This reinforces ARG-007’s potential as a breakthrough neuroprotective therapy.

Vulcan Energy has begun mobilising its advanced V20 drilling rig to the Schleidberg site in Germany, marking a key milestone in its Phase One Lionheart Project to produce sustainable lithium for electric vehicle batteries.

Vonex Limited has announced a $13.9 million non-renounceable entitlement offer primarily aimed at reducing its debt, alongside the upcoming departure of CEO Ian Porter. Major shareholder MaxoTel is backing the raise with a substantial commitment.

Rapid Lithium Limited has closed its partially underwritten entitlement offer, raising $53,860 with 37 applications, and is now working to place the remaining shortfall by April 2025.

Noxopharm has successfully completed key in vitro safety tests for its SOF-SKN™ lupus drug, paving the way for the upcoming HERACLES Phase 1 clinical trial.

Philsaga Mining Corporation has announced a delay in the completion of its Tigerway decline at the Co-O Mine, citing COVID-19 disruptions and a significant earthquake as key factors. The company is now focusing on horizontal drives to improve ore transport and ventilation, with full decline completion expected by year-end 2025.

Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.

Lucapa Diamond Company is grappling with a blockade at its Lulo Alluvial Diamond Mine in Angola, disrupting mining operations and risking first-quarter production. Ongoing talks aim to resolve the standoff amid community demands deemed unreasonable by the company.

dorsaVi has secured a new commercial research project with renowned US surgeon Dr. Chirag Patel, leveraging its FDA-cleared wearable sensor technology and AI to enhance injury prevention and performance for elite athletes.